Lung cancer screening is an annual low-dose CT scan of the chest designed to detect lung cancer early, before symptoms appear. It’s recommended for adults aged 50 to 80 who have a significant smoking history, and large clinical trials show it reduces the chance of dying from lung cancer by about 20%. Despite that benefit, relatively few eligible people actually get screened, partly because many don’t know the option exists.
How the Scan Works
The screening itself is a low-dose computed tomography scan, often called LDCT. You lie on a table while an X-ray machine takes detailed cross-sectional images of your lungs. The whole process takes only a few minutes, requires no injections or contrast dye, and isn’t painful. You breathe normally or hold your breath briefly while the images are captured.
The “low-dose” part matters. A standard chest CT delivers roughly 7 millisieverts of radiation. An LDCT uses significantly less, typically around 1 to 1.5 millisieverts, which is closer to what you absorb naturally from background radiation over six months. That lower dose is enough to spot small nodules in lung tissue while keeping cumulative radiation exposure manageable over years of annual screening.
Who Qualifies for Screening
The U.S. Preventive Services Task Force recommends annual LDCT screening for adults who meet all three of these criteria:
- Age 50 to 80
- 20 pack-year smoking history (one pack-year equals smoking one pack a day for one year, so one pack a day for 20 years, two packs a day for 10 years, and similar combinations all count)
- Current smoker or quit within the past 15 years
Screening should stop once you’ve been smoke-free for 15 years, or if you develop a health condition that would substantially limit your life expectancy or your ability to undergo treatment if cancer were found. The point of screening is catching something treatable, so it only makes sense when treatment is a realistic option.
What the Evidence Shows
The case for screening rests on two landmark trials. The National Lung Screening Trial (NLST), which enrolled over 53,000 people in the U.S., found a 20% reduction in lung cancer deaths among those screened with LDCT compared to those who received standard chest X-rays. The Dutch-Belgian NELSON trial found a similar reduction. A later meta-analysis pooling nine eligible trials confirmed the benefit, finding an overall 16% reduction in lung cancer mortality across studies.
That reduction comes down to stage at diagnosis. Lung cancer caught at stage I or II is far more treatable than cancer discovered after it has spread. Screening shifts the balance toward earlier detection, when surgery alone can often be curative.
False Positives and Their Consequences
The most common downside of screening is a false positive: the scan flags something that turns out not to be cancer. This happens more often than many people expect. In the NLST, the false-positive rate was about 24% on the first screening round. A systematic review of 20 studies found a median false-positive rate of roughly 20% on initial scans, dropping to about 9.5% on follow-up scans as radiologists establish a baseline for comparison.
Most false positives lead to nothing more than a repeat scan in a few months. Small lung nodules are extremely common, especially in current and former smokers, and the vast majority are benign. Only about 1.8% of NLST participants without lung cancer ended up having an invasive procedure (like a biopsy or surgery) because of a positive screening result. Among all false positives in the trial, just 0.06% led to a major complication from a follow-up procedure.
Still, a false positive can cause real anxiety. Waiting three months for a follow-up scan to confirm a nodule hasn’t grown is stressful, even when the odds are strongly in your favor. That emotional cost is worth considering alongside the mortality benefit.
How Results Are Categorized
Radiologists use a standardized system called Lung-RADS to classify what they see on your scan. The categories range from 1 (negative, nothing suspicious) to 4 (suspicious findings that need further workup). Here’s what the main categories mean for you in practical terms:
- Category 1 or 2: No cancer suspected. You return for your regular annual screening in 12 months. Category 2 means a benign-appearing nodule was noted but doesn’t need any extra follow-up.
- Category 3: A nodule that’s probably benign but warrants a closer look. You’ll typically get a repeat LDCT in six months to check whether it’s changed.
- Category 4A: A more suspicious finding. You’ll likely have a follow-up LDCT in three months or a PET scan. If the nodule stays the same size or shrinks, it gets downgraded to category 3, then eventually back to routine screening.
- Category 4B: A finding suspicious enough to warrant direct diagnostic evaluation, which may include a biopsy.
The stepped approach is designed to avoid unnecessary biopsies. Many nodules that initially look concerning turn out to be stable or shrinking on follow-up, and the system allows them to be reclassified without invasive testing.
Insurance Coverage and Cost
Under the Affordable Care Act, most private insurance plans must cover lung cancer screening with no out-of-pocket cost for people who meet the eligibility criteria. Medicare also covers annual LDCT screening, though with a slightly narrower age window of 50 to 77.
Before your first screening, Medicare requires a counseling and shared decision-making visit. During this visit, your provider confirms your eligibility, discusses the benefits and limitations of screening (including false positives), and talks about smoking cessation if you’re still smoking. This visit doesn’t need to be with a physician specifically. It can be with a nurse practitioner, physician assistant, or other qualified provider. After that initial visit, you simply need an order for the annual scan going forward.
What Screening Cannot Do
LDCT screening is effective but not perfect. It misses some cancers, particularly those that grow rapidly between annual scans. It also detects some slow-growing cancers that might never have caused harm during a person’s lifetime, a phenomenon called overdiagnosis. The exact rate of overdiagnosis is debated, but it means some people undergo treatment for cancers that wouldn’t have affected them.
Screening also only applies to people with a significant smoking history. Lung cancer does occur in never-smokers, but the rate is low enough that the harms of screening (radiation exposure, false positives, unnecessary procedures) would outweigh the benefits in that population. If you’ve never smoked and have no other major risk factors, LDCT screening is not recommended for you, even if you have a family history of lung cancer.
For those who do qualify, the math favors screening. A 20% reduction in lung cancer death is substantial for a test that takes minutes, carries minimal radiation, and is covered by insurance. The key is getting screened consistently, every year, so that changes can be caught and tracked over time.